Expression of AIF and HtrA2/Omi in small lymphocytic lymphoma and diffuse large B-cell lymphoma.
Apoptosis-inducing factor is a 57-kDa protein encoded by "programmed cell death 8" gene located on the X chromosome in humans. (24) It has been known that AIF has both apoptosis and nicotinamide adenine dinucleotide oxidase activities. (25) In physiologic situations, AIF is a nicotinamide adenine dinucleotide oxidase with a local redox function in the mitochondria. It acts as a free radical scavenger and protects cells from cell death induced by oxidative stresses. (26,27) The mitochondrial level of AIF has been recently associated with tumorigenicity of various carcinoma cell types. (25) Apoptosis-inducing factor promotes apoptosis through a caspase-independent pathway. Upon release from mitochondria, AIF is translocated to the nucleus where it binds to the chromosome via its C-terminal nuclear localization sequence and causes DNA condensation and fragmentation. (24,28) Apoptosis-inducing factor lacks intrinsic nuclease activity and its DNA degrading activity depends on the recruitment of downstream nucleases. Studies have showed the cooperation of AIF with endonuclease G, a DNAse of mitochondrial origin that is involved in the caspase-independent pathway, in Caenorhabditis elegans and mammals. (29,30) Dual functions of AIF have been proposed: The prosurvival function of AIF plays a crucial role in tumorigenesis, whereas the apoptotic activity of AIF might contribute to cancer cell death induced by some agents including chemotherapy.
HtrA2/Omi is a 37-kDa serine protease located in the mitochondrial intermembrane space that plays an important physiologic role in mitochondrial homeostasis. (31) Upon apoptotic stimulation, it is released into the cytosol, where it contributes to apoptosis through both caspase-dependent and caspase-independent pathways. Similar to Smac/DIABLO, HtrA2/Omi binds to and neutralizes IAPs (XIAP, cIAP1, and cIAP2) via its N-terminal IAP-binding motif, therefore releasing the inhibition of IAP to caspase-3, -7, and -9. It also exerts its proapoptotic function via its protease activity, independent of IAP and caspase. (31,32)
Because AIF and HtrA2/Omi both play important roles in apoptosis, analysis of their expression is necessary to understand the pathogenesis of cancer. The expression of AIF and HtrA2/Omi has been studied in some tumors or tumor cell lines, such as colorectal carcinoma, esophageal squamous carcinoma EC9706 cells, gastric carcinoma, and renal cell carcinoma. (33-38) However, little is known about their expression in lymphomas. In this study, we have used immunohistochemical method to assess the expression of AIF and Omi/HtrA2 in SLL/CLL and DLBCL.
MATERIALS AND METHODS
This study was approved by the University of Alabama at Birmingham institutional review board.
The study group included 43 surgically resected lymphomas, which included 23 DLBCL cases and 20 cases of SLL/CLL. The control group included 10 cases of benign/reactive lymphnodes. These cases were retrieved from surgical pathology archives of the University of Alabama at Birmingham Hospital. The clinical history, pathology reports, and hematoxylin-eosin-stained slides were reviewed to confirm the diagnosis.
Immunohistochemical staining was performed on serial paraffin-embedded sections of human lymphoid tissue using UltraVision One detection system (HRP polymer and DAB Plus chromogen, Thermo Fisher Scientific, Fremont, California). The 4-|im-thick tissue sections were deparaffinized and incubated with Ultra V Block for 5 minutes to block nonspecific binding. The sections were then incubated with either AIF antibody (rabbit polyclonal, 1:50 dilution, Cell Signaling, Massachusetts) or HtrA2/Omi antibody (rabbit monoclonal, 1:50 dilution, Epitomics, California) overnight at 4[degrees]C. After washing in Tris buffered saline 0.025% Triton X-100, the slides were incubated in hydrogen peroxide block for 10 minutes. After washing in Tris buffered saline buffer, they were incubated with UltraVision One HRP Polymer (second antibodies) for 30 minutes, followed by staining with DAB Plus chromogen and substrate. Counterstaining was performed with hematoxylin. For both AIF and HtrA2/ Omi stains, cytoplasmic immunoreactivity in tumor cells, regardless of intensity, was considered a positive reaction. In positive cases, positivity was always present in greater than 50% of tumor cells. The intensity ranged from low (1+) to moderate (2+) to strong (3+). All stains were reviewed independently by 2 pathologists.
The 2-tailed Fisher exact test was performed to compare the expression of AIF and HtrA2/Omi between DLBCL and SLL/ CLL. A P value of less than .05 was considered statistically significant.
The patients' age, sex, and tumor location are summarized in Table 1. The cases were of DLBCL include 8 GCB, 9 non-GCB, and 6 remaining cases of undetermined subtypes. The SLL/CLL includes 2 cases with either prolymphocytic or large cell transformation. Apoptosis-inducing factor immunostaining, when present, was detected in the cell cytoplasm with a fine or coarse granular pattern. In reactive lymph nodes, moderate to strong AIF immunoreactivity was detected in the lymphoid cells of follicular centers of 10 benign/ reactive lymph nodes (Figure 1, A). Some follicular dendritic cells and histiocytes also showed cytoplasmic stain. The frequency of AIF expression in DLBCL and SLL/CLL is summarized in Table 2. Apoptosis-inducing factor was strongly and diffusely expressed in 15 of 23 cases of DLBCL (Figure 1, B). There is no difference in the AIF expression level and pattern between GCB and non-GCB subgroups of DLBCL. The expression of AIF was detected in 15 of 20 SLL/CLL with most cases showing weak positivity (Figure 1, C). Unlike DLBCL, SLL/CLL demonstrates a heterogeneous AIF expression pattern characterized by predominantly positive staining in large cells and increased intensity in pseudofollicles (Figure 1, C through E). A strong and diffuse staining of AIF was noted in the areas with either prolymphocytic or large cell transformation in 2 CLLs/SLLs (Figure 1, F).
[FIGURE 1 OMITTED]
[FIGURE 2 OMITTED]
In contrast, HtrA2/Omi immunostain was only weakly expressed in 17 of 20 cases of SLL/CLL (85%), 18 of 23 cases of DLBCL (78%), and the follicular center and mantle zone of 10 benign lymph nodes (Figure 2, A through C). It is difficult to tell if it is true positivity or background staining. There is no increased intensity of HtrA2/Omi in 2 cases of SLL/CLL with either prolymphocytic or large cell transformation (Figure 2, D).
Overall, the expression of AIF was stronger in DLBCL than in SLL/CLL, but there was no significant difference in the frequency of expression between these 2 lymphomas (P > .05). For HtrA2/Omi expression, both the frequency and intensity showed no significant difference (P > .05).
Deregulation of apoptosis is not only involved in the development of hematopoietic malignancies but also frequently associated with the resistance to anticancer therapies, including chemotherapy, radiation, or immunotherapy. (5,39) The apoptosis machinery of cells is tightly regulated by proapoptotic and antiapoptotic proteins. Knowing the expression pattern of these proapoptotic and antiapoptotic proteins is the necessary step to understand the pathogenesis of hematopoietic malignancies and further aids the development of targeted therapy. To our knowledge, the expression of 2 proapoptotic proteins, AIF and HtrA2/Omi, in lymphomas has not been examined to date. In our present study, we have shown that AIF is expressed in germinal center lymphoid cells and some histiocytes and dendritic cells of normal/reactive lymph nodes. It is detectable in more than 80% of DLBCLs and SLLs/CLLs with the expression level much higher in DLBCL than in SLL/CLL. HtrA2/Omi is similarly and weakly expressed in all normal/reactive lymph nodes, DLBCLs, and SLLs/CLLs.
SLL/CLL results from an accumulation of malignant small B cells due to an imbalance between cell proliferation and death rates. This imbalance may be caused by increased cell proliferation, decreased death, or a combination of both processes. It is believed that both low proliferative rate and decreased cell death or a defect in apoptosis play a role in clinical indolent non-Hodgkin lymphomas such as SLL/CLL. Our results of weak expression of AIF and HtrA2/Omi in SLL/CLL, combined with previous studies of total lack of Smac/DIABLO expression (9) and variable expression of cIAP1 and cIAP2 in SLL/CLL, (21) appear to support the notion that this lymphoma is characterized by defective apoptosis. However, the weak and cytoplasmic expression of AIF may indicate that AIF does not play a critical role as either a prosurvival or an apoptotic factor in CLL/SLL. Interestingly, because the expression of AIF is largely located in large cells and proliferation centers of SLL/CLL, and highly and diffusely increased in the areas of either prolymphocytic or large cell transformation, the increased level or diffuse staining pattern of AIF in those areas of SLL/CLL may indicate a potential role of AIF in promoting cell proliferation and transformation to an aggressive disease course.
Clinically aggressive non-Hodgkin lymphomas such as DLBCL are highly proliferative and may be associated with either low or high level apoptosis. It has been shown that Smac/DIABLO is highly expressed in approximately 53% of DLBCLs. (9) Our current study demonstrated that AIF is strongly expressed in most cases of DLBCL. High frequency and level of AIF and Smac/DIABLO in DLBCL may indicate that both caspase-dependent and caspase-independent apoptotic pathways are functionally active in this lymphoma. Because apoptosis is strictly regulated by multiple proapoptotic and antiapoptotic proteins, the actual apoptotic rate in DLBCL also depends on other factors like IAPs. Our data indicate no difference of AIF expression between GCB and non-GCB subgroups of DLBCL.
An important fact about AIF is its double functions. (25) Normally, AIF is located in the mitochondria and involved in the oxidative phosphorylation process. After apoptotic stimuli, it is released to the cytoplasm from mitochondria and further translocates to the nucleus to induce apoptosis. Apparently, translocation to the nucleus is critical for its proapoptotic function. Both previous studies in other tumors and our results in SLL/CLL and DLBCL showed AIF expression in the cytoplasm. Is there any unknown factor that inhibits its translocation to the nucleus? Does this possible inhibition contribute to the defect of apoptosis? Alternatively, the strong cytoplasmic expression of AIF may represent a major prosurvival function of AIF in tumorigenesis and progression in DLBCL, while the apoptotic activity of AIF may contribute to cell death induced by apoptotic stimuli such as chemotherapy, and the nuclear expression of AIF may be a temporary phenomenon that is unable to be detected in this study. A lot of details are still unclear and much work needs to be done to further elucidate the regulation of AIF functions.
Apoptosis-inducing factor, a major player in caspase-independent apoptosis, is a very promising drug target. In lymphomas with low or defective expression of AIF, such as SLL/CLL, administration or overexpression of AIF or its agonist and use of reagents that can increase its mitochondrial release and translocation to nuclei theoretically could induce tumor cell apoptosis and serve as an anticancer therapy. Several drugs, such as BZL101 and Antiprimod, that induce AIF to release from mitochondria have undergone phase I or II clinical trial and demonstrated promising antitumor activity. (40) Both in vitro study and animal studies have shown that Antiprimod has a potential in the treatment of multiple myeloma, mantle cell lymphoma, and other advanced cancers. (41) Because it is thought that SLL/CLL commonly demonstrates decreased apoptosis and the resistance of DLBCL to chemotherapy may be due to an apoptotic defect, we postulate that Antiprimod may sensitize these lymphoma cells to apoptosis induced by chemotherapy or immunotherapy; therefore, it may enhance chemotherapy and/or immunotherapy for SLL/CLL and DLBCL, particularly for chemotherapy-refractory DLBCL. However, extensive and detailed studies are required before any possible conclusion can be made.
HtrA2/Omi plays a pivotal role in both caspase-dependent and caspase-independent apoptotic pathways, which makes it a valuable therapeutic target. Our results of low expression of HtrA2/Omi in DLBCL and SLL/CLL suggest that administration of HtrA2/Omi or its agonist, or use of reagents that increase its mitochondrial release, theoretically could induce tumor cell apoptosis. This may make it a possible therapeutic target for developing new drugs for these lymphomas.
In summary, the different expression of AIF and HtrA2/Omi in CLL/SLL and DLBCL suggests different apoptotic mechanisms involved in the pathogenesis of these diseases. High frequency and level of AIF and Smac/DIABLO (previous studies) in DLBCL indicate that both caspase-dependent and caspase-independent apoptotic pathways are functionally active in this lymphoma. Weak expression of AIF and lack of Smac/DIABLO (previous studies) in CLL/SLL suggests that apoptosis in this neoplasm is not active. Weak expression of HtrA2/ Omi in CLL/SLL, DLBCL, and benign/reactive lymph nodes suggests that HtrA2/Omi may not be a major proapoptotic protein in these disease entities. The results may help us to better understand the pathogenesis of these lymphomas and also may benefit new drug development for these lymphomas. Additional studies are required to further elucidate the roles of these proapoptotic proteins in the pathogenesis of these lymphomas.
(1.) Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239-257.
(2.) Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805): 770-776.
(3.) Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
(4.) Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106(2):408-418.
(5.) Fulda S. Cell death in hematological tumors. Apoptosis. 2009;14(4):409-423.
(6.) Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol. 2003;4(3):211-218.
(7.) Kast RE, Altschuler EL. Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha. Arch Immunol Ther Exp. 2005; 53(2):143-147.
(8.) Pallasch CP, Wendtner CM. Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(3):498-501.
(9.) Ren Y, Akyurek N, Schlette E, Rassidakis GZ, Medeiros LJ. Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas. Hum Pathol. 2006;37(11):1407-1413.
(10.) Danilov AV, Danilova OV, Klein AK, Huber BT. Molecular pathogenesis of chronic lymphocytic leukemia. Curr Mol Med. 2006;6(6):665-675.
(11.) Muris JJ, Meijer CJ, Ossenkoppele GJ, Vos W, Oudejans JJ. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma. Hematol Oncol. 2006;24(3):97-104.
(12.) Muris JJ, Ylstra B, Cillessen SA, et al. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. Br J Haematol. 2007;136(1):38-47.
(13.) Troutaud D, Petit B, Bellanger C, et al. Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(2):118-124.
(14.) Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4(2):139-163.
(15.) Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007;39(7-8):1462-1475.
(16.) Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17(6):1675-1687.
(17.) Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004;23(16):2861-2874.
(18.) Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998; 281(5381):1312-1316.
(19.) Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004;64(20):7183-7190.
(20.) de Graaf AO, van Krieken JH, Tonnissen E, et al. Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol. 2005;130(6):852-859.
(21.) Akyurek N, Ren Y, Rassidakis GZ, Schlette EJ, Medeiros LJ. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer. 2006;107(8):1844-1851.
(22.) Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000;6(5):1796-1803.
(23.) Wrzesien-Kus A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T. The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis. 2004;9(6):705-715.
(24.) Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397(6718):441-446.
(25.) Porter AG, Urbano AG. Does apoptosis-inducing factor (AIF) have both life and death functions in cells? Bioessays. 2006;28(8):834-843.
(26.) Klein JA, Longo-Guess CM, Rossmann MP, et al. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature. 2002;419(6905): 367-374.
(27.) Miramar MD, Costantini P, Ravagnan L, et al. NADH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem. 2001;276(19):16391-16398.
(28.) Ye H, Cande C, Stephanou NC, et al. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat Struct Biol. 2002;9(9):680-684.
(29.) Wang X, Yang C, Chai J, Shi Y, Xue D. Mechanisms of AIF-mediated apoptotic DNA degradation in Caenorhabditis elegans. Science. 2002;298(5598): 1587-1592.
(30.) Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K. BUB1 mediation of caspase-independent mitotic death determines cellfate. J Cell Biol. 2007;178(2): 283-296.
(31.) Vande Walle L, Lamkanfi M, Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ. 2008;15(3):453-460.
(32.) Li W, SrinivasulaSM, Chai J, et al. Structuralinsights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Nat Struct Biol. 2002;9(6): 436-441.
(33.) Guan JT, Wang L, Wang Y, et al. Expression of AIF and caspase-3 in colorectal carcinoma, adenoma, and normal mucosa and its correlation [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2009;12(4):391-394.
(34.) Fan T, Jiang G, Suo Z, et al. Down-regulation of the apoptosis-inducing factor or Bcl-2 inhibitor of transcription by RNA interference can alleviate TAp63gamma-induced apoptosis in esophageal squamous carcinoma EC9706 cells. Int J Oncol. 2009;35(2):359-367.
(35.) Jeong EG, Lee JW, Soung YH, et al. Immunohistochemical and mutational analysis of apoptosis-inducing factor (AIF) in colorectal carcinomas. APMIS. 2006;114(12):867-873.
(36.) Lee JW, Jeong EG, Soung YH, et al. Immunohistochemical analysis of apoptosis-inducing factor (AIF) expression in gastric carcinomas. Pathol Res Pract. 2006;202(7):497-501.
(37.) Kempkensteffen C, Hinz S, Christoph F, et al. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol. 2008; 134(5):543-550.
(38.) Lee SH, Lee JW, Kim HS, et al. Immunohistochemical analysis of Omi/HtrA2 expression in stomach cancer. APMIS. 2003;111(5):586-590.
(39.) Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798-4811.
(40.) Lorenzo HK, Susin SA. Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Resist Updat. 2007;10(6):235-255.
(41.) Wang M, Zhang L, Han X, et al. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007;109(12):5455-5462.
Shaoying Li, MD; Mei Wan, MD, PhD; Xu Cao, PhD; Yongsheng Ren, MD, PhD
Accepted for publication September 10, 2010.
From the Department of Pathology, University of Alabama at Birmingham Health System, Birmingham. Dr Li is now with the Department of Hematopathology, University of Texas M. D. Anderson Cancer Center, Houston.
The authors have no relevant financial interest in the products or companies described in this article.
Presented as a platform presentation at the annual meeting of the American Society of Clinical Pathology resident research symposium, Chicago, Illinois, October 31, 2009.
Reprints: Shaoying Li, MD, Department of Hematopathology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 72, Houston, TX 77030 (e-mail: firstname.lastname@example.org).
Table 1. Summary of Patient and Lymphoma Characteristics Diagnosis No. of Age, y Mean Sex, No. Cases (range) M F DLBCL 23 60 (37-84) 12 11 SLL/CLL 20 63 (51-81) 11 9 Benign LN 10 39 (14-68) 6 4 Diagnosis Tumor Location, No. LN Neck Mediastinum Other DLBCL 11 4 4 4 (a) SLL/CLL 19 1 0 0 Benign LN 0 0 0 0 Abbreviations: Benign LN, benign/reactive lymph node; DLBCL, diffuse large B-cell lymphoma; LN, lymph node; SLL/CLL, small lymphocytic lymphoma/chronic lymphocytic leukemia. (a) Including 1 thyroid, 1 lacrimal gland, 1 testis, and 1 retroperitoneal mass. Table 2. Summary of Immunoreactivity of Apoptosis-Inducing Factor (AIF) and High Temperature Requirement Protein 1 A2 (HtrA2) Diagnosis No. of AIF Cases +++ ++ + - Positive, % P (a) DLBCL 23 15 2 2 4 83 SLL/CLL 20 2 2 11 5 75 .71 Diagnosis HtrA2/Omi +++ ++ + - Positive, % P (a) DLBCL 0 1 17 5 78 SLL/CLL 0 0 17 3 85 .70 Abbreviations: DLBCL, diffuse large B-cell lymphoma; SLL/CLL, small lymphocytic lymphoma/chronic lymphocytic leukemia. (a) P value by 2-tailed Fisher exact test to compare the positive % of AIF and HtrA2/Omi between DLBCL and SLL/CLL.
|Printer friendly Cite/link Email Feedback|
|Author:||Li, Shaoying; Wan, Mei; Cao, Xu; Ren, Yongsheng|
|Publication:||Archives of Pathology & Laboratory Medicine|
|Date:||Jul 1, 2011|
|Previous Article:||Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens.|
|Next Article:||[CD34.sup.+] cell enumeration by flow cytometry: a comparison of systems and methodologies.|